You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTamoxifen
Accession NumberDB00675  (APRD00123)
TypeSmall Molecule
GroupsApproved
Description

One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium. [PubChem]

Structure
Thumb
Synonyms
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-tamox
Citofen
Crisafeno
Diemon
Gen-tamoxifen
Istubol
Noltam
Nourytam
Oncomox
Retaxim
Tamofen
Tamone
Tamoxasta
Tamoxifen
Tamoxifène
Tamoxifene
Tamoxifeno
Tamoxifenum
trans-Tamoxifen
Valodex
Zemide
External Identifiers
  • ICI-46474
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-tamoxifentablet20 mgoralDominion PharmacalNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-tamoxifentablet10 mgoralDominion PharmacalNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-tamoxifentablet20 mgoralMylan Pharmaceuticals Ulc1994-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-tamoxifentablet10 mgoralMylan Pharmaceuticals Ulc1994-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nolvadex Tab 10mgtablet10 mgoralAstrazeneca Canada Inc1994-12-312003-04-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nolvadex-D Tab 20mgtablet20 mgoralAstrazeneca Canada Inc1995-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-tamoxifen Tabletstablet20 mgoralPentapharm Ltd.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-tamoxifen Tabletstablet10 mgoralPentapharm Ltd.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-tamoxifentablet20 mgoralPharmascience Inc1998-12-01Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-tamoxifentablet10 mgoralPharmascience Inc1998-12-01Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Soltamoxliquid10 mg/5mLoralRosemont Pharmaceuticals Ltd2012-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamofen 10tablet10 mgoralSanofi Aventis Canada Inc1986-12-312011-01-11Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamofen 20tablet20 mgoralSanofi Aventis Canada Inc1986-12-312011-01-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamone - (10 Mg)tablet10 mgoralPfizer Canada Inc1996-12-312007-10-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamone - (20 Mg)tablet20 mgoralPfizer Canada Inc1996-12-312007-10-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamone Tab 10mgtablet10 mgoralAdria Laboratories Of Canada Ltd.1989-12-311996-09-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamone Tab 20mgtablet20 mgoralAdria Laboratories Of Canada Ltd.1989-12-311996-09-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamoplex Tab 10mgtablet10 mgoralDupont Merck Pharma Inc.1992-12-311996-09-09Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamoplex Tab 20mgtablet20 mgoralDupont Merck Pharma Inc.1992-12-311996-09-09Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamoxifentablet20 mgoralPharmel Inc1999-09-28Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamoxifentablet10 mgoralPharmel Inc1999-09-28Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamoxifene - 10tablet10 mgoralPro Doc Limitee2007-10-292011-07-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamoxifene - 20tablet20 mgoralPro Doc Limitee2007-10-292011-07-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-tamoxifentablet20 mgoralTeva Canada Limited1990-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-tamoxifentablet10 mgoralTeva Canada Limited1990-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tamox Tab 10mgtablet10 mgoralApotex Inc1989-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-tamox Tab 20mgtablet20 mgoralApotex Inc1989-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tamoxifen Citratetablet, film coated20 mg/1oralTeva Pharmaceuticals USA Inc2003-02-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet, film coated10 mg/1oralPhysicians Total Care, Inc.1994-04-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet20 mg/1oralWatson Laboratories, Inc.2011-08-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet10 mg/1oralWatson Laboratories, Inc.2011-08-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet20 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet20 mg/1oralMylan Pharmaceuticals Inc.2003-02-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet10 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet10 mg/1oralMylan Pharmaceuticals Inc.2003-02-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet10 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-09-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet, film coated10 mg/1oralKAISER FOUNDATION HOSPITALS2008-03-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet20 mg/1oralbryant ranch prepack2011-03-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2003-02-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tamoxifen Citratetablet, film coated20 mg/1oralPhysicians Total Care, Inc.2005-01-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AdifenMedicamerc
AdopanSawai Seiyaku
BilemTeva Int'l
CaditamCadila
CitofenNot Available
CrisafenoLKM
DoctamoxifeneDocpharma
EbefenEbewe
FenahexSandoz
GenoxMerck Serono
GynatamBiogalenic
IstubalAstraZeneca
MammonexCP Pharmaceuticals
NeophedanAspen Pharmacare
NoltamNot Available
NolvadexAstraZeneca
Nolvadex-DAstraZeneca
NovofenRemedica
OncomoxSun
TadexOrion
TamifenMedochemie
TamizamMithra
TamofenSanofi-Aventis
TamoneprinActavis
TamoplexPharmachemie
TamoxenAscent
TamoxilonCelon
TamteroHetero
TecnotaxZodiac
TomifenAlkem
ValodexNot Available
ZemideNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tamoxifen Citrate
54965-24-1
Thumb
  • InChI Key: FQZYTYWMLGAPFJ-OQKDUQJOSA-N
  • Monoisotopic Mass: 563.251917165
  • Average Mass: 563.6381
DBSALT000168
Categories
UNII094ZI81Y45
CAS number10540-29-1
WeightAverage: 371.5146
Monoisotopic: 371.224914555
Chemical FormulaC26H29NO
InChI KeyInChIKey=NKANXQFJJICGDU-QPLCGJKRSA-N
InChI
InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
IUPAC Name
(2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine
SMILES
CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassStilbenes
Sub ClassNot Available
Direct ParentStilbenes
Alternative Parents
Substituents
  • Stilbene
  • Diphenylmethane
  • Phenylpropene
  • Phenylpropane
  • Phenol ether
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationTamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ.
PharmacodynamicsTamoxifen belongs to a class of drugs called selective estrogen receptor modulators (SERMs), which have both estrogenic and antiestrogenic effects. Tamoxifen has the same nucleus as diethylstilbestrol but possesses an additional side chain (trans isomer) which accounts for its antiestrogenic activity.
Mechanism of actionTamoxifen is a nonsteroidal agent that binds to estrogen receptors (ER), inducing a conformational change in the receptor. This results in a blockage or change in the expression of estrogen dependent genes. The prolonged binding of tamoxifen to the nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both estrogenic and antiestrogenic effects.
AbsorptionWhen a single oral dose of 20 mg is given, the average peak plasma concentration (Cmax) is 40 ng/mL which occurred approximately 5 hours after dosing (Tmax). The Cmax of N-desmethyl tamoxifen is 15 ng/mL. Steady-state concentrations for tamoxifen is achieved in 4 weeks, while steady-state concentrations for N-desmethyl tamoxifen is achieved in 8 weeks.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Tamoxifen is extensively metabolized after oral administration. N-Desmethyl-tamoxifen is the major metabolite found in plasma. N-Desmethyl-tamoxifen's activity is similar to tamoxifen. 4-hydroxy-tamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. 4-Hydroxy-tamoxifen formation is catalyzed mainly by cytochrome P450 (CYP) 2D6, and also by CYP2C9 and 3A4. At high tamoxifen concentrations, CYP2B6 also catalyzes 4-hydroxylation of the parent drug. 4-Hydroxy-tamoxifen possesses 30- to 100-times greater affinity for the estrogen receptor and 30- to 100-times greater potency at inhibiting estrogen-dependent cell proliferation compared to tamoxifen. It is also metabolized by flavin monooxygenases FMO1 and FMO3 to form tamoxifen-N-oxide.

SubstrateEnzymesProduct
Tamoxifen
N-DesmethyltamoxifenDetails
Tamoxifen
4-HydroxytamoxifenDetails
Tamoxifen
3-Hydroxytamoxifen (Droloxifene)Details
Tamoxifen
Tamoxifen N-oxideDetails
Tamoxifen
Alpha-hydroxytamoxifenDetails
Tamoxifen
Tamoxifen-N-glucuronideDetails
4-Hydroxytamoxifen
EndoxifenDetails
Alpha-hydroxytamoxifen
Not Available
Alpha-hydroxy-tamoxifen-O-glucuronideDetails
4-Hydroxytamoxifen
4-hydroxytamoxifen sulfateDetails
4-Hydroxytamoxifen
4-hydroxytamoxifen-N-glucuronideDetails
4-Hydroxytamoxifen
4-hydroxytamoxifen-O-glucuronideDetails
N-Desmethyltamoxifen
alpha-Hydroxy-N-desmethyltamoxifenDetails
N-Desmethyltamoxifen
EndoxifenDetails
Endoxifen
Endoxifen sulfateDetails
Endoxifen
Not Available
NorendoxifenDetails
Endoxifen
Endoxifen O-glucuronideDetails
N-Desmethyltamoxifen
N-Didesmethyl-tamoxifenDetails
4-Hydroxytamoxifen
3,4-Dihydroxy-tamoxifenDetails
Tamoxifen
4'-HydroxytamoxifenDetails
4-Hydroxytamoxifen
cis-4-HydroxytamoxifenDetails
Tamoxifen N-oxide
alpha-Hydroxytamoxifen N-oxideDetails
Alpha-hydroxytamoxifen
alpha-Hydroxytamoxifen N-oxideDetails
Alpha-hydroxytamoxifen
Not Available
alpha-Hydroxy-N-desmethyltamoxifenDetails
Route of elimination65% of the dose was excreted from the body over 2 weeks in which fecal excretion was the primary route of elimination. Tamoxifen is excreted mainly as polar conjugates, with unchanged drug and unconjugated metabolites accounting for less than 30% of the total fecal radioactivity.
Half lifeThe decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.
Clearance

Clearance (CL/F) as body weight adjusted in female pediatric patients was approximately 2.3-fold higher than in female breast cancer patients.

ToxicitySigns observed at the highest doses following studies to determine LD50 in animals were respiratory difficulties and convulsions.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A Allele, homozygotePoor response to drug treatment, shorter time to relapse17115111
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Coagulation factor V
Gene symbol: F5
UniProt: P12259
rs6025 Not AvailableA alleleBreast cancer patients taking tamoxifen as part of treatment regimine are more likely to experience a thromboembolic event.20554945
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.997
Blood Brain Barrier+0.5838
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.7718
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.6225
Renal organic cation transporterInhibitor0.6715
CYP450 2C9 substrateNon-substrate0.8071
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateInhibitor0.8535
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorInhibitor0.8448
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5054
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6058
BiodegradationNot ready biodegradable0.9048
Rat acute toxicity1.9882 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7402
hERG inhibition (predictor II)Inhibitor0.6898
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Rosemont group ltd
  • Astrazeneca pharmaceuticals lp
  • Aegis pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Pharmachemie bv
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Watson laboratories inc florida
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tabletoral20 mg
Liquidoral10 mg/5mL
Tabletoral10 mg/1
Tabletoral20 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Prices
Unit descriptionCostUnit
Tamoxifen citrate powder50.03USD g
Nolvadex 20 mg tablet4.46USD tablet
Tamoxifen Citrate 20 mg tablet3.94USD tablet
Tamoxifen 20 mg tablet3.79USD tablet
Nolvadex 10 mg tablet2.04USD tablet
Tamoxifen Citrate 10 mg tablet1.97USD tablet
Tamoxifen 10 mg tablet1.89USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States61274251998-06-262018-06-26
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point97 °CPhysProp
water solubility0.000167 mg/mL at 25 °CMEYLAN,WM et al. (1996)
logP7.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00102 mg/mLALOGPS
logP5.93ALOGPS
logP6.35ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity128.43 m3·mol-1ChemAxon
Polarizability44.19 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Chengjian Mao, “Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells.” U.S. Patent US20030199022, issued October 23, 2003.

US20030199022
General References
  1. Jordan VC: Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 2006 Jan;147 Suppl 1:S269-76. Pubmed
  2. Jordan VC: Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 1993 Oct;110(2):507-17. Pubmed
  3. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7;365(9453):60-2. Pubmed
  4. Steiner AZ, Terplan M, Paulson RJ: Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod. 2005 Jun;20(6):1511-5. Epub 2005 Apr 21. Pubmed
  5. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG: Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med. 2006 Jan 17;144(2):101-6. Pubmed
  6. FDA label
External Links
ATC CodesL02BA01
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (102 KB)
MSDSDownload (74.8 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Abiraterone resulting in a loss in efficacy.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Tamoxifen.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Tamoxifen.
AmiodaroneThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Amiodarone resulting in a loss in efficacy.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Tamoxifen.
AnastrozoleThe serum concentration of Anastrozole can be decreased when it is combined with Tamoxifen.
BexaroteneThe serum concentration of Tamoxifen can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Tamoxifen can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Tamoxifen.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Tamoxifen.
BupropionThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Bupropion resulting in a loss in efficacy.
CelecoxibThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Celecoxib resulting in a loss in efficacy.
ChloroquineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Chloroquine resulting in a loss in efficacy.
ChlorpromazineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Chlorpromazine resulting in a loss in efficacy.
CimetidineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cimetidine resulting in a loss in efficacy.
CinacalcetThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cinacalcet resulting in a loss in efficacy.
CitalopramTamoxifen may increase the QTc-prolonging activities of Citalopram.
ClobazamThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Clobazam resulting in a loss in efficacy.
ClomipramineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Clomipramine resulting in a loss in efficacy.
ClozapineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Clozapine resulting in a loss in efficacy.
CocaineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cocaine resulting in a loss in efficacy.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Tamoxifen.
ConivaptanThe serum concentration of Tamoxifen can be increased when it is combined with Conivaptan.
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tamoxifen.
DabrafenibThe serum concentration of Tamoxifen can be decreased when it is combined with Dabrafenib.
DarifenacinThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Darifenacin resulting in a loss in efficacy.
DasatinibThe serum concentration of Tamoxifen can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Tamoxifen can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Delavirdine resulting in a loss in efficacy.
DesipramineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Desipramine resulting in a loss in efficacy.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Tamoxifen.
DiphenhydramineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Diphenhydramine resulting in a loss in efficacy.
DofetilideTamoxifen may increase the QTc-prolonging activities of Dofetilide.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Tamoxifen.
DronedaroneThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Dronedarone resulting in a loss in efficacy.
DuloxetineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Duloxetine resulting in a loss in efficacy.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Tamoxifen.
EliglustatThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Eliglustat resulting in a loss in efficacy.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Tamoxifen.
FloxuridineThe metabolism of Tamoxifen can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Tamoxifen can be decreased when combined with Fluconazole.
FluoxetineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Fluoxetine resulting in a loss in efficacy.
FosaprepitantThe serum concentration of Tamoxifen can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Tamoxifen can be increased when it is combined with Fusidic Acid.
GoserelinTamoxifen may increase the QTc-prolonging activities of Goserelin.
HaloperidolThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Haloperidol resulting in a loss in efficacy.
IdelalisibThe serum concentration of Tamoxifen can be increased when it is combined with Idelalisib.
ImipramineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Imipramine resulting in a loss in efficacy.
IsoniazidThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Isoniazid resulting in a loss in efficacy.
IvacaftorThe serum concentration of Tamoxifen can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ketoconazole resulting in a loss in efficacy.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Tamoxifen.
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Tamoxifen.
LeuprolideTamoxifen may increase the QTc-prolonging activities of Leuprolide.
LorcaserinThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Lorcaserin resulting in a loss in efficacy.
LuliconazoleThe serum concentration of Tamoxifen can be increased when it is combined with Luliconazole.
MethadoneThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Methadone resulting in a loss in efficacy.
MethotrimeprazineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Methotrimeprazine resulting in a loss in efficacy.
MifepristoneThe serum concentration of Tamoxifen can be increased when it is combined with Mifepristone.
MipomersenTamoxifen may increase the hepatotoxic activities of Mipomersen.
MirabegronThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Mirabegron resulting in a loss in efficacy.
MitotaneThe serum concentration of Tamoxifen can be decreased when it is combined with Mitotane.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Tamoxifen.
NelfinavirThe metabolism of Tamoxifen can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Tamoxifen can be increased when it is combined with Netupitant.
NicardipineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Nicardipine resulting in a loss in efficacy.
NilotinibThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Nilotinib resulting in a loss in efficacy.
OspemifeneThe risk or severity of adverse effects can be increased when Tamoxifen is combined with Ospemifene.
PalbociclibThe serum concentration of Tamoxifen can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Tamoxifen can be increased when it is combined with Panobinostat.
ParoxetineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Paroxetine resulting in a loss in efficacy.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Tamoxifen.
Peginterferon alfa-2bThe serum concentration of Tamoxifen can be decreased when it is combined with Peginterferon alfa-2b.
PhenytoinThe metabolism of Tamoxifen can be increased when combined with Phenytoin.
PromazineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Promazine resulting in a loss in efficacy.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Tamoxifen.
QuinidineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Quinidine resulting in a loss in efficacy.
QuinineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Quinine resulting in a loss in efficacy.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Tamoxifen.
RifabutinThe metabolism of Tamoxifen can be increased when combined with Rifabutin.
RifampicinThe metabolism of Tamoxifen can be increased when combined with Rifampicin.
RifapentineThe metabolism of Tamoxifen can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Tamoxifen.
RitonavirThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ritonavir resulting in a loss in efficacy.
RolapitantThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Rolapitant resulting in a loss in efficacy.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Tamoxifen.
SecobarbitalThe metabolism of Tamoxifen can be increased when combined with Secobarbital.
SertralineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Sertraline resulting in a loss in efficacy.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Tamoxifen.
SiltuximabThe serum concentration of Tamoxifen can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Tamoxifen can be increased when it is combined with Simeprevir.
St. John's WortThe serum concentration of Tamoxifen can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Stiripentol resulting in a loss in efficacy.
SulfisoxazoleThe metabolism of Tamoxifen can be decreased when combined with Sulfisoxazole.
TerbinafineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Terbinafine resulting in a loss in efficacy.
ThioridazineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Thioridazine resulting in a loss in efficacy.
TiclopidineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ticlopidine resulting in a loss in efficacy.
TipranavirThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tipranavir resulting in a loss in efficacy.
TocilizumabThe serum concentration of Tamoxifen can be decreased when it is combined with Tocilizumab.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Tamoxifen.
TorasemideThe metabolism of Torasemide can be decreased when combined with Tamoxifen.
TranylcypromineThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tranylcypromine resulting in a loss in efficacy.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Tamoxifen.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Tamoxifen.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Tamoxifen.
Food InteractionsNot Available

Targets

1. Estrogen receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist agonist

Components

Name UniProt ID Details
Estrogen receptor P03372 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69. Pubmed
  3. Fabian CJ, Kimler BF: Chemoprevention for high-risk women: tamoxifen and beyond. Breast J. 2001 Sep-Oct;7(5):311-20. Pubmed
  4. Cyrus K, Wehenkel M, Choi EY, Lee H, Swanson H, Kim KB: Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs. ChemMedChem. 2010 Jul 5;5(7):979-85. Pubmed

2. Estrogen receptor beta

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist agonist

Components

Name UniProt ID Details
Estrogen receptor beta Q92731 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Chen B, Gajdos C, Dardes R, Kidwai N, Johnston SR, Dowsett M, Jordan VC: Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. Int J Oncol. 2005 Aug;27(2):327-35. Pubmed
  3. Horner-Glister E, Maleki-Dizaji M, Guerin CJ, Johnson SM, Styles J, White IN: Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells. J Mol Endocrinol. 2005 Dec;35(3):421-32. Pubmed
  4. Girault I, Bieche I, Lidereau R: Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas. 2006 Jul 20;54(4):342-51. Epub 2006 Jul 5. Pubmed
  5. Mc Ilroy M, Fleming FJ, Buggy Y, Hill AD, Young LS: Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Endocr Relat Cancer. 2006 Dec;13(4):1135-45. Pubmed
  6. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, Peterson C, Malmstrom P, Isola J, Borg A, Ferno M: Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res. 2007 Apr 1;13(7):1987-94. Pubmed
  7. Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69. Pubmed
  8. Hayes DF, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V, Li L, Philips S, Desta Z, Flockhart DA: Estrogen Receptor Genotypes, Menopausal Status, and the Effects of Tamoxifen on Lipid Levels: Revised and Updated Results. Clin Pharmacol Ther. 2010 Sep 8. Pubmed

3. 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Q15125 Details

References:

  1. Paul R, Silve S, De Nys N, Dupuy PH, Bouteiller CL, Rosenfeld J, Ferrara P, Le Fur G, Casellas P, Loison G: Both the immunosuppressant SR31747 and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian Delta8-Delta7 sterol isomerase. J Pharmacol Exp Ther. 1998 Jun;285(3):1296-302. Pubmed

4. Protein kinase C

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Protein kinase C alpha type P17252 Details
Protein kinase C beta type P05771 Details
Protein kinase C delta type Q05655 Details
Protein kinase C epsilon type Q02156 Details
Protein kinase C gamma type P05129 Details
Protein kinase C iota type P41743 Details
Protein kinase C theta type Q04759 Details
Protein kinase C zeta type Q05513 Details

References:

  1. O’Brian CA, Liskamp RM, Solomon DH, Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res. 1985 Jun;45(6):2462-5. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Higgins MJ, Stearns V: CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15. Pubmed
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  4. Kuderer NM, Peppercorn J: CYP2D6 testing in breast cancer: ready for prime time? Oncology (Williston Park). 2009 Dec;23(14):1223-32. Pubmed, Link.
  5. Goetz MP: Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor. Oncology (Williston Park). 2009 Dec;23(14):1233-4, 1236. Pubmed, Link.
  6. Desta Z, Ward BA, Soukhova NV, Flockhart DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. Epub 2004 May 24. Pubmed
  7. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74. Pubmed
  8. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  3. Desta Z, Ward BA, Soukhova NV, Flockhart DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. Epub 2004 May 24. Pubmed
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  5. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. Pubmed

3. Cytochrome P450 3A5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 3A7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

5. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Desta Z, Ward BA, Soukhova NV, Flockhart DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. Epub 2004 May 24. Pubmed
  3. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74. Pubmed
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 2B6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2B6 P20813 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Desta Z, Ward BA, Soukhova NV, Flockhart DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. Epub 2004 May 24. Pubmed
  3. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74. Pubmed
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

8. Cytochrome P450 1A1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A1 P04798 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

9. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74. Pubmed

10. Cytochrome P450 1B1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1B1 Q16678 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

11. Dimethylaniline monooxygenase [N-oxide-forming] 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Dimethylaniline monooxygenase [N-oxide-forming] 1 Q01740 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

12. Dimethylaniline monooxygenase [N-oxide-forming] 3

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Dimethylaniline monooxygenase [N-oxide-forming] 3 P31513 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

13. Cytochrome P450 2C8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

14. Liver carboxylesterase 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Liver carboxylesterase 1 P23141 Details

References:

  1. Fleming CD, Bencharit S, Edwards CC, Hyatt JL, Tsurkan L, Bai F, Fraga C, Morton CL, Howard-Williams EL, Potter PM, Redinbo MR: Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol. 2005 Sep 9;352(1):165-77. Pubmed

15. Cytochrome P450 19A1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Aromatase P11511 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

16. Cytochrome P450 2A6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2A6 P11509 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

17. Cytochrome P450 2E1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

18. UDP-glucuronosyltransferase 1-4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-4 P22310 Details

References:

  1. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P: Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14. Epub 2007 Jul 30. Pubmed

19. Sulfotransferase 1A1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Sulfotransferase 1A1 P50225 Details

References:

  1. Hertz DL, McLeod HL, Irvin WJ Jr: Tamoxifen and CYP2D6: a contradiction of data. Oncologist. 2012;17(5):620-30. doi: 10.1634/theoncologist.2011-0418. Epub 2012 Apr 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Riley J, Styles J, Verschoyle RD, Stanley LA, White IN, Gant TW: Association of tamoxifen biliary excretion rate with prior tamoxifen exposure and increased mdr1b expression. Biochem Pharmacol. 2000 Jul 15;60(2):233-9. Pubmed
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. Pubmed
  3. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. Pubmed
  4. Bekaii-Saab TS, Perloff MD, Weemhoff JL, Greenblatt DJ, von Moltke LL: Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. Biopharm Drug Dispos. 2004 Oct;25(7):283-9. Pubmed
  5. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. Pubmed
  6. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. Pubmed

2. ATP-binding cassette sub-family G member 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
ATP-binding cassette sub-family G member 2 Q9UNQ0 Details

References:

  1. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW: Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51. Epub 2003 Mar 28. Pubmed

3. Bile salt export pump

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Bile salt export pump O95342 Details

References:

  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. Pubmed

4. Canalicular multispecific organic anion transporter 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Canalicular multispecific organic anion transporter 1 Q92887 Details

References:

  1. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H: Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010 Mar 10;28(8):1287-93. doi: 10.1200/JCO.2009.25.7246. Epub 2010 Feb 1. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11